Nxera Pharma (4565) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Corporate strategy and vision

• Announced rebranding to Nxera Pharma, aiming to lead the next era of medicine with a global mindset and operations across Japan, UK, Switzerland, and Korea.

• Focuses on innovative biotech breakthroughs, leveraging the NxWave GPCR platform, with over 1,500 patents and 10+ active discovery programs targeting up to 400 GPCRs.

• Prioritizes high-growth therapeutic areas: neurology, neuropsychiatry, metabolic disease, immunology, and GI, with a strategic focus on both wholly-owned R&D and licensing.

• Aims to grow top-line revenue from JPY 11 billion to at least JPY 50 billion by 2029-2030, targeting a 26% CAGR.

• Employs over 400 staff across five global locations, combining commercial, clinical, and technical expertise.

Financial and operational highlights

• Reported annual revenues nearing $200 million (JPY29bn) and $250 million in liquidity (JPY36bn cash), supporting R&D and licensing.

• Two commercial products in Japan—Pivlaz (2022) and Quvivic (2024)—are driving top-line growth, with expansion plans in Korea and APAC.

• Maintains a lean, efficient sales force, generating over JPY 400 million per rep annually.

• Royalty and milestone revenues from partnered programs are expected to drive a step-change in profitability, with WAVE1 and WAVE2 launches projected by 2030 and 2035.

• Holds over 1,500 granted patents and more than 10 discovery programs in progress.

Product and pipeline developments

• Pivlaz has achieved rapid market penetration in Japan for aSAH, expected to reach JPY 20 billion peak sales in 4-5 years.

• Quvivic, a dual orexin receptor antagonist for insomnia, is positioned as best-in-class and targets Japan’s $1 billion sleep drug market.

• Neurocrine partnership advances muscarinic agonists for schizophrenia; NBI-568 showed positive Phase 2 results in 2024 and is set for Phase 3 in 2025.

• Centessa’s ORX750, an orexin-2 agonist for narcolepsy, is in Phase 2A with data expected in 2025; Pfizer’s PFE-522, an oral GLP-1 agonist for diabetes/obesity, is in Phase 1 with updates in 2025.

• Wholly-owned pipeline includes first-in-class and best-in-class assets in schizophrenia, advanced solid tumors, and IBD, with multiple Phase 1 and 1b studies ongoing.